dc.contributor.author | Smrke, A | |
dc.contributor.author | Anderson, PM | |
dc.contributor.author | Gulia, A | |
dc.contributor.author | Gennatas, S | |
dc.contributor.author | Huang, PH | |
dc.contributor.author | Jones, RL | |
dc.date.accessioned | 2021-01-22T15:53:42Z | |
dc.date.issued | 2021-01-15 | |
dc.identifier.citation | Cells, 2021, 10 (1) | |
dc.identifier.issn | 2073-4409 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4310 | |
dc.identifier.eissn | 2073-4409 | |
dc.identifier.doi | 10.3390/cells10010172 | |
dc.description.abstract | Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy. | |
dc.format | Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Future Directions in the Treatment of Osteosarcoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-01-13 | |
rioxxterms.versionofrecord | 10.3390/cells10010172 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-01-15 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cells | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.publication-status | Published | |
pubs.volume | 10 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Molecular and Systems Oncology | |
dc.contributor.icrauthor | Huang, Paul | |